Revenue qualityDanger
매출 흑자인데 영업CF 적자 (OCF/매출 -77%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Oscotec
A039200 · KOSDAQ₩38,250+4.22%
2026-08-25 closeOscotec — pricey right now, or cheap? And what signals are flashing today?
The grade and valuation bands are below — free to read.
Loading chart…
Close
AI Insight
Why these signals fired — only backtest-proven edge, told honestly
New high + volume — the real recordrecord · not a prediction
Not this one stock, but every new-high-plus-volume pick we actually published (Korea market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-25)
Last 30 sessions
402 picks
Next-day win rate
51.6%
Avg next-day
-0.06%
vs market
-0.24%p
Beat the market on 45.3% of picks (each pick vs its own day’s market average).
Recent publish days (next-day win rate)
08-23 60%08-21 36.4%08-20 44.4%08-19 0%08-18 27.3%08-14 23.1%08-13 41.7%08-12 70%08-11 77.8%08-10 22.2%08-07 61.5%08-06 27.3%
This stock has not flashed this signal recently — the record above is the signal’s own, not this stock’s.
Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.
Trade plan
Decide the exit before you enter. Set what you are willing to lose first, and the share count follows — so you know the worst case before you buy.
Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.
This is a calculator, not advice, and it does not promise any outcome. You choose the stop and target — the button values (ATR, recent low/high) are observations from past prices. Actual fills depend on the order book and liquidity.
Valuation Grades
Relative to 292 건강관리 peers · not investment advice
B+
Overall: 건강관리 101/292 · top 35%
Factor composite · relative position in sector
Valuation in its own history
PER 1669.51 · PBR 11.45 — own history (2007-01~) percentiles 88/100 · 43/100
PER88/100
PBR43/100
Higher indicates lower valuation relative to its history (based on earnings and book yields).
Earnings percentiles can fluctuate for cyclical companies (including loss periods), so the book basis is shown alongside. Companies with large share buybacks can have structurally high PBR. Factual information, not investment advice.
Financial safety
Reference indicatorAs of 2024Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 4.35
Distress
Grey
Safe
- Altman Z''
- 4.35
- Beneish M-Score
- 4.27
- Sloan accrual
- 15.76%
Statistical manipulation-risk signal
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
7/9Strong
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score7/9
Profitability
- Positive ROAPass
- Positive OCFNot passed
- Improving ΔROAPass
- Accruals (OCF > net income)Not passed
Leverage & liquidity
- Lower debtPass
- Higher current ratioPass
- No new sharesPass
Efficiency
- Higher gross marginPass
- Higher asset turnoverPass
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Revenue qualityWarning
매출채권 증가율이 매출 증가율의 1.5배 초과 (3기 연속) — 매출 인식 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Cash conversion cycleWarning
현금전환주기(CCC) 3기 연속 확대 — 운전자본 경색·현금 회수 지연 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Margin trendWarning
영업외손익 급변 (영업이익 대비 120% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Factual information, not investment advice.
Industry structure
KRAs of 2026-08-25건강관리
This stock is in 건강관리: revenue rank 182 of 287, share 0.1%.
182 / 2870.1%revenue share
Who dominates this industry?
- 1삼성바이오로직스7.3%
- 2셀트리온5.7%
- 3녹십자홀딩스3.5%
- 4유한양행3.3%
- 5대웅3.1%
- 6오스코텍0.1%
Concentration
DistributedCR3 16.6%HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.
Polarization
Winner-take-all deepeningConsistentPolarization measures industry gaps and structure, not valuation, forecast, or investment advice.
Margin lens
- IQR%p
- 31.61
- Direction
- 확대
- Level
- 넓음
- Years
- 7
Value lens
- P90/P10
- 14
- Median P/B
- 1.47
- Level
- 넓음
- n
- 263
Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- -10%
- Interest coverage
- -3.1x
- Return on equity (ROE)
- 0.7%
Operating margin −5pp
Operating lossInterest coverageBase -3.1x adverse case -4.7x
Return on equity (ROE)Base 0.7% adverse case -4.9%
Revenue −15%
Interest coverage riskInterest coverageBase -3.1x adverse case -2.7x
Return on equity (ROE)Base 0.7% adverse case -3.1%
Interest rate +2pp
Interest coverage riskInterest coverageBase -3.1x adverse case -1.8x
Return on equity (ROE)Base 0.7% adverse case -4.2%
Interest coverage limit
Already below the limit by 13.2ppInterest coverage limit at an operating margin of 3.2%
Interest expense coverage threshold
Key suppliers · Annual report
Annual reportDART · 2026-03-19Suppliers disclosed by the company in its 2026-03-19 annual report.
Purchase amount
KRW 100m- BoneKRW 75.1B
- OPBKRW 75.1B
Suppliers without disclosed amount
SynCeraInduCeraBioCera
Financials at a glance
Oscotec's latest results and balance sheet. The bars track the last three periods.
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.
5%+ major-holding disclosures
- 김정근12.67%2025-04-18 · 증감 -0.19%p
- 김성연12.45%2026-08-14 · 증감 0.00%p
- 타이거자산운용투자일임5.09%2026-05-22 · 증감 +0.40%p
Other stocks held by the same investors
A filing-based shared-holder record, not investment advice.
- 한국화장품제조KRA003350 →
Shared holders: 타이거자산운용투자일임
- 한신공영KRA004960 →
Shared holders: 타이거자산운용투자일임
- 웅진KRA016880 →
Shared holders: 타이거자산운용투자일임
- LB세미콘KRA061970 →
Shared holders: 타이거자산운용투자일임
- 디티앤씨KRA187220 →
Shared holders: 타이거자산운용투자일임
- 인카금융서비스KRA211050 →
Shared holders: 타이거자산운용투자일임
- 아우딘퓨쳐스KRA227610 →
Shared holders: 타이거자산운용투자일임
- 에스바이오메딕스KRA304360 →
Shared holders: 타이거자산운용투자일임
Connections
AI-extracted related companies · for reference
Competitors
Same theme
Recent filings
Oscotec's latest filings on Korea's DART. Open a headline for a reference summary and the original.
Source: DART (Korea electronic disclosure)
Like these rules? Run them automatically.
Quantus turns rules like these into backtests and automated trading — same team, free to start.
Quantus Signal · live data · not investment advice · Privacy Policy